trial

Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

NCTId NCT07467993
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Recruiting
Enrollment 142 (estimated)
Sponsored by Novartis Pharmaceuticals
Primary completion 2027-07-29
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Recruiting
Enrollment
142 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2026-03-16
Primary completion
2027-07-29
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
GXV813

Sponsors

Novartis PharmaceuticalsLead Sponsor

Sites

12 total
Bentonville, United StatesPico Rivera, United StatesMiami, United StatesDecatur, United StatesChicago, United StatesChicago, United StatesSt Louis, United StatesKazanlak, BulgariaLovech, BulgariaSofia, BulgariaVeliko Tarnovo, BulgariaVratsa, Bulgaria

Linked catalysts

1
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Ho — primary completion2027-07-29

Facts & assertions

4 sourced
Enrollment
142
Phase
PHASE2
Primary Completion Date
2027-07-29
Status
RECRUITING
relationships
The graph out of here
drug
GXV813
drug
lead_sponsor
Novartis Pharmaceuticals
company
indication
Schizophrenia
indication
Schizophrenia
indication